What the Medical Literature Reports About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Inquiry

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. These symptoms have been documented in medical literature over decades of pharmacovigilance for various medications. This page reviews the published case reports and research examining a possible link between Ozempic and gastroparesis.

Understanding Gastroparesis and Ozempic's Mechanism

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Its clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, with symptoms persisting for at least three months. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its mechanism includes slowing gastric emptying, which contributes to its glucose-lowering effect but also underlies gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Warning Adequacy

The pharmacologic action of GLP-1 receptor agonists includes delayed gastric emptying, which is a desired effect for glycemic control but can mimic or exacerbate gastroparesis symptoms. The slowing of gastric motility is mediated through vagal and enteric nervous system pathways. While the label does not explicitly list gastroparesis as an adverse reaction, the reported gastrointestinal effects—nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—overlap with gastroparesis symptoms. The dose-dependent increase in gastrointestinal adverse reactions suggests a mechanistic link: higher doses of Ozempic produce greater delays in gastric emptying, potentially leading to symptomatic gastroparesis in susceptible individuals. The current prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis. The label notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and clinicians unaware of the potential for this serious condition. Given the overlap in symptoms and the known effect on gastric emptying, the adequacy of warnings is questionable. Patients with pre-existing gastroparesis or risk factors (e.g., diabetes, prior gastric surgery) may be particularly vulnerable.

Causation and Timeline Considerations

For patients who develop gastroparesis symptoms after starting Ozempic, establishing causation requires careful evaluation. Key considerations include: (1) temporal relationship—symptoms typically emerge during dose escalation or within weeks of initiation; (2) exclusion of other causes (e.g., mechanical obstruction, medication-induced, idiopathic); (3) dose-response relationship—higher doses are associated with greater gastrointestinal adverse reactions; and (4) dechallenge and rechallenge—symptoms may improve upon discontinuation and recur with re-exposure. The label reports that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo, and discontinuation rates were higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, individual susceptibility varies, and not all patients develop severe symptoms. The majority of gastrointestinal adverse reactions, including nausea and vomiting, occurred during dose escalation, suggesting a relatively short latency period (weeks to months). In clinical trials, patients receiving Ozempic 0.5 mg and 1 mg experienced higher rates of gastrointestinal adverse reactions compared to placebo, with discontinuation rates of 3.1% and 3.8%, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The timeline for progression to gastroparesis is less clear, as the label does not specifically document this outcome. However, persistent symptoms despite dose adjustment may indicate chronic gastric dysmotility. Post-marketing reports and case series have described gastroparesis in patients using GLP-1 receptor agonists, though the label does not quantify this risk.

Conclusion and Clinical Implications

The evidence indicates that Ozempic can cause gastrointestinal adverse reactions that overlap with gastroparesis symptoms, and its pharmacologic effect on gastric emptying provides a plausible mechanistic link. The current warnings do not specifically address gastroparesis, which may be a gap in risk communication. For affected patients, a careful assessment of temporal relationship, dose-response, and exclusion of other causes is essential. The timeline between exposure and harm is typically during dose escalation, but chronic cases may occur. Clinicians should monitor for signs of gastroparesis and consider discontinuation if symptoms are severe or persistent.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can mimic or exacerbate gastroparesis symptoms. Clinical trials show higher rates of gastrointestinal adverse reactions like nausea and vomiting compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label does not explicitly list gastroparesis, the overlapping symptoms and dose-dependent effects suggest a potential causal link.

What are the symptoms of gastroparesis caused by Ozempic?

Symptoms include early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. These overlap with common gastrointestinal side effects of Ozempic, such as nausea, vomiting, dyspepsia, and gastroesophageal reflux disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

How long after starting Ozempic can gastroparesis develop?

Gastrointestinal adverse reactions typically occur during dose escalation, within weeks to months of starting Ozempic. In clinical trials, most reports of nausea and vomiting emerged during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Chronic gastroparesis may develop if symptoms persist despite dose adjustment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.